ICU Management of HRS/AKI and Multiorgan Failure in Patients With Decompensating Cirrhosis-Part 3

Video Transcription

Video Summary

The transcript discusses the treatment of hepatorenal syndrome type acute kidney injury, focusing on the use of vasoconstrictors like terlipressin in combination with albumin as recommended by different medical societies. Terlipressin is preferred as the first-line therapy over alternatives like norepinephrine and octreotide due to its efficacy in improving renal function. The transcript highlights data from studies, such as the confirmed trial, demonstrating the benefits of terlipressin in reversing hepatorenal syndrome. It also addresses considerations for patient selection, administration, monitoring, and potential adverse effects of terlipressin, including respiratory issues and volume overload. The importance of early treatment, monitoring urine output, and the role of renal replacement therapy and liver transplantation in managing hepatorenal syndrome are also discussed.

Keywords

hepatorenal syndrome

acute kidney injury

vasoconstrictors

terlipressin

albumin

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.